Selepressin: complete guide

Selepressin is a vasopressin analog that targets the V1a receptor. Its phase 2b/3 septic shock trial was stopped for futility, and it is not FDA-approved.

Complete guide5 min read

Key takeaway

Selepressin is a ring-shaped peptide of 9 residues weighing 1,048.3 g/mol. In the SEPSIS-ACT trial of 868 patients, ventilator- and vasopressor-free days were 15.0 with selepressin and 14.5 with placebo (P = .30). Ninety-day mortality was 40.6% vs 39.4%.

At a glance

Article typeComplete guide
Regulatory statusNot FDA-approved“Selepressin is not approved by the FDA for any use.” (this article)
ClassHeart & blood
Body systemsHeart & vessels
Studies cited4 in this article · 4 across 1 article on Selepressin
Related productsResearch peptide catalog

Selepressin is a synthetic analog of the hormone vasopressin, designed to act on the V1a receptor and not the V2 receptor. Ferring Pharmaceuticals tested it in septic shock. Its phase 2b/3 trial was stopped early for futility. This guide covers its structure, mechanism, trials, side effects and status. Sources were checked on November 17, 2026.

Quick answer: Selepressin is an investigational selective vasopressin V1a receptor agonist, not an approved drug. Its main trial, SEPSIS-ACT, did not improve its primary outcome and was terminated for futility. ClinicalTrials.gov lists no selepressin trial started after it. Related peptides with their own guides include vasopressin and terlipressin.

Vitrapep does not sell selepressin; this page is a reference summary of published research and regulatory information.

What is selepressin?

Selepressin is a vasopressin analog made of nine amino acid residues. Two cysteines are linked by a disulfide bond, which closes most of the chain into a ring. PubChem lists the sequence as H-Cys(1)-Phe-Ile-hGln-Asn-Cys(1)-Pro-Orn(iPr)-Gly-NH2 (PubChem CID 53330936).

PubChem also names it as human vasopressin with different residues at positions 2, 3, 4 and 8. It gives the formula C46H73N13O11S2 and a molecular weight of 1,048.3 g/mol. Its development code was FE 202158. It counts as a peptide because it is a short chain of amino acids. See our vasopressin guide for the parent hormone and our peptide primer for the basics.

Table 1

Selepressin: key facts

Fact Detail
Structure type Cyclic peptide of 9 residues with a disulfide bond and an amidated end
Class Selective vasopressin V1a receptor agonist (investigational)
Molecular formula C46H73N13O11S2
Molecular weight 1,048.3 g/mol
Development stage Phase 2b/3 trial (SEPSIS-ACT) terminated for futility in 2018
Sponsor or developer Ferring Pharmaceuticals

How does selepressin work?

Natural arginine vasopressin activates both V1a and V2 receptors. Selepressin was built to activate V1a only. Boucheix and colleagues called it “a new selective vasopressin V1a agonist for treatment of vasodilatory hypotension in shock” (Boucheix et al., 2013). In healthy anesthetized dogs, selepressin and vasopressin raised mean blood pressure to a similar degree. Selepressin showed no relevant coronary ischemic liability.

The case for avoiding V2 came from a sheep model of severe sepsis caused by Pseudomonas aeruginosa pneumonia. Septic sheep retained about 7 liters of fluid over 24 hours. Vasopressin partly reduced this build-up, while selepressin “almost completely blocked” it (Maybauer et al., 2014). Adding the V2 agonist desmopressin raised fluid accumulation back to vasopressin levels. The authors concluded that selepressin’s lack of V2 activity explained the difference. These are animal data.

What is selepressin being studied for?

Selepressin is not approved by the FDA for any use. All of its registered trials enrolled patients with septic shock who needed vasopressor drugs to support blood pressure. Ferring Pharmaceuticals sponsored each one:

  • phase 2, 53 patients, completed 2011 (NCT01000649);
  • phase 2, 31 patients with early septic shock, completed 2013 (NCT01612676); and
  • phase 2b/3 SEPSIS-ACT, 868 patients, ended February 2018, status “Terminated due to futility” (NCT02508649).

ClinicalTrials.gov lists no selepressin trial started after SEPSIS-ACT. We found no Ferring announcement about the program’s future. Development appears inactive, but no sponsor statement confirms that.

What did the key trials show?

Phase 2a. This randomized, double-blind, placebo-controlled, multicenter trial enrolled 53 patients with early septic shock. Open-label norepinephrine was added if blood pressure fell below target. In one selepressin group, more patients than with placebo kept mean arterial pressure above 60 mmHg without norepinephrine. The share was about 50% at 12 hours and 70% at 24 hours (p < 0.01). That group also needed less norepinephrine overall than placebo and had a lower fluid balance from day 5 (Russell et al., 2017).

SEPSIS-ACT. This adaptive phase 2b/3 trial ran at 63 hospitals in Belgium, Denmark, France, the Netherlands and the United States. It randomized 868 patients: 585 to one of three selepressin regimens and 283 to placebo. The primary endpoint was ventilator- and vasopressor-free days within 30 days, with deaths scored as zero (Laterre et al., 2019).

Results were 15.0 days with selepressin and 14.5 days with placebo. The difference was 0.6 days (95% CI −1.3 to 2.4; P = .30). Ninety-day mortality was 40.6% vs 39.4% (P = .77). Kidney replacement therapy-free days and ICU-free days also did not differ. The trial stopped for futility at the end of part 1, which was meant to pick the best regimen. Both trials were in humans.

What side effects have studies reported?

SEPSIS-ACT reported these adverse events for selepressin vs placebo (Laterre et al., 2019):

  • cardiac arrhythmias: 27.9% vs 25.2%;
  • cardiac ischemia: 6.6% vs 5.6%;
  • mesenteric (gut) ischemia: 3.2% vs 2.6%; and
  • peripheral ischemia: 2.3% vs 2.3%.

In the phase 2a trial, treatment-emergent adverse events occurred at a similar frequency to placebo (Russell et al., 2017). Two patients entered the highest-level group. Treatment was stopped in one for possible safety reasons, and that group was closed.

What is selepressin’s regulatory status, and how is it used in research?

Selepressin is an investigational compound. A search of fda.gov returned no FDA approval, designation, warning letter or import alert naming it. Its registry record for SEPSIS-ACT lists posted results.

In research, selepressin helps separate V1a effects from V2 effects in animal models of shock and sepsis. The sheep and dog studies above are examples. For related peptides studied in shock, see our guides to terlipressin and angiotensin II.

Frequently asked questions about selepressin

Is selepressin a peptide?

Yes. It is a ring-shaped vasopressin analog of nine residues, closed by a disulfide bond.

How is selepressin different from vasopressin?

Vasopressin activates V1a and V2 receptors. Selepressin was designed to activate V1a only, to avoid V2-linked fluid leak seen in animal studies.

Is selepressin FDA approved?

No. It reached phase 2b/3 testing, which ended for futility in 2018.

Why was SEPSIS-ACT stopped?

It was stopped for futility at the end of part 1. Ventilator- and vasopressor-free days did not differ from placebo.

Did selepressin reduce deaths in septic shock?

No. Ninety-day mortality was 40.6% with selepressin and 39.4% with placebo.

What to know now

  • Structure: 9-residue cyclic vasopressin analog; 1,048.3 g/mol.
  • Mechanism: selective V1a receptor agonist, without V2 activity.
  • Evidence: SEPSIS-ACT (868 patients) showed no benefit on its primary endpoint.
  • Mortality: 40.6% vs 39.4% at 90 days.
  • Safety: arrhythmias 27.9% vs 25.2%; ischemic events similar to placebo.
  • Status: not FDA-approved; no trial registered after 2018.

What we’re watching

ClinicalTrials.gov lists no active selepressin study as of November 17, 2026. We will update this page if a new trial is registered or Ferring states its plans. Related guides: vasopressin, terlipressin and angiotensin II.

More for heart & vessels

All 13 compounds for heart & vessels

Sources: National Center for Biotechnology Information 2026, PubChem compound summary for CID 53330936, selepressin; Laterre 2019, JAMA, 322; Russell 2017, Critical Care, 21; Maybauer 2014, Critical Care Medicine, 42; Boucheix 2013, Shock, 39; Ferring Pharmaceuticals 2015; Ferring Pharmaceuticals 2009, Effects of the V1a agonist FE 202158 in patients with septic shock; Ferring Pharmaceuticals 2012. All 8 citations

Back to the research library

References

  1. National Center for Biotechnology Information. (2026). PubChem compound summary for CID 53330936, selepressin. Retrieved November 17, 2026, from https://pubchem.ncbi.nlm.nih.gov/compound/53330936
  2. Laterre, P. F., Berry, S. M., Blemings, A., et al. (2019). Effect of selepressin vs placebo on ventilator- and vasopressor-free days in patients with septic shock: The SEPSIS-ACT randomized clinical trial. JAMA, 322(15), 1476-1485. https://doi.org/10.1001/jama.2019.14607
  3. Russell, J. A., Vincent, J. L., Kjølbye, A. L., et al. (2017). Selepressin, a novel selective vasopressin V1A agonist, is an effective substitute for norepinephrine in a phase IIa randomized, placebo-controlled trial in septic shock patients. Critical Care, 21(1), 213. https://doi.org/10.1186/s13054-017-1798-7
  4. Maybauer, M. O., Maybauer, D. M., Enkhbaatar, P., et al. (2014). The selective vasopressin type 1a receptor agonist selepressin (FE 202158) blocks vascular leak in ovine severe sepsis. Critical Care Medicine, 42(7), e525-e533. https://doi.org/10.1097/CCM.0000000000000300
  5. Boucheix, O. B., Milano, S. P., Henriksson, M., et al. (2013). Selepressin, a new V1A receptor agonist: Hemodynamic comparison to vasopressin in dogs. Shock, 39(6), 533-538. https://doi.org/10.1097/SHK.0b013e31828aac4b
  6. Ferring Pharmaceuticals. (2015). Selepressin Evaluation Programme for Sepsis-Induced Shock: Adaptive Clinical Trial (SEPSIS-ACT) (ClinicalTrials.gov ID NCT02508649). Retrieved November 17, 2026, from https://clinicaltrials.gov/study/NCT02508649
  7. Ferring Pharmaceuticals. (2009). Effects of the V1a agonist FE 202158 in patients with septic shock (ClinicalTrials.gov ID NCT01000649). Retrieved November 17, 2026, from https://clinicaltrials.gov/study/NCT01000649
  8. Ferring Pharmaceuticals. (2012). Investigating FE 202158 as potential primary treatment in patients with early septic shock (ClinicalTrials.gov ID NCT01612676). Retrieved November 17, 2026, from https://clinicaltrials.gov/study/NCT01612676